NEW YORK (GenomeWeb News) – Quidel announced after the close of the market on Thursday the 510(k) clearance by the US Food and Drug Administration of the company's AmpliVue HSV 1+2 Assay for differentiating and detecting herpes simplex viruses 1 and 2.

The assay is for use on Quidel's handheld AmpliVue molecular diagnostic device and requires no upfront DNA extraction. Results can be obtained in about one hour, the San Diego-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.